The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per ...

Fintel reports that on June 27, 2025, Clear Street downgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from Buy ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers. Did ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

When Mayor Michelle Wu announced in April that an anonymous donor had given $1 million to the Boston Arts Academy in the closing stretch of a six-year campaign, and would give another $1 million if ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The Boston Arts Academy Foundation received a $1 million gift from Joshua Boger, the founder and former CEO of Vertex ...

Vertex Pharmaceuticals caught the eye of deep-pocketed investors, triggering a spike in unusual options activity. Benzinga’s ...

Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

U.S. multinational company Abbott entered a partnership with Abu Dhabi's Department of Health to manufacture medicines in the ...